Company news
Nanobiotix SA news in 2025
Nanobiotix SA's news releases, calls and decks from 2025, newest first.
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
December 15, 2025
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
November 24, 2025
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
November 13, 2025
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
November 11, 2025
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
November 3, 2025
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
October 31, 2025
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
October 24, 2025
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
October 1, 2025
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
September 30, 2025
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
September 29, 2025
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
September 17, 2025
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
July 7, 2025
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
May 28, 2025
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
May 21, 2025
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
May 12, 2025
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
May 5, 2025
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
April 30, 2025
Calls in 2025
Decks in 2025
- Investor Presentation (January 2025)
Investor deck · 43 slides · January 2025